Metagenomics platform drives biomarker and drug discovery
• By Suzanne Elvidge
Enterome will use its metagenomics platform to develop drugs that target the effects of alterations in the microbiota, and to identify, develop and commercialize biomarkers. The company's biomarkers will be used to develop diagnostics, and to stratify populations, identifying those most likely to respond to treatment. Enterome is focused on metabolic and bowel diseases, with lead projects in nonalcoholic steatohepatitis and in inflammatory bowel disease.
